June 20, 2024

Antidepressant Drugs Market Size to Worth USD 25.22 Billion By 2033

The global antidepressant drugs market size accounted for US$ 18.5 billion in 2023 and is projected to reach around USD 25.22 billion by 2033, growing at a CAGR of 3.20% from 2024 to 2033.

Key Takeaways

  • North America contributed 46.50% market share in 2023.
  • By product, the selective serotonin reuptake inhibitors segment dominated the market in 2023.
  • By depressive disorder, the major depressive disorder segment is expected to sustain its dominance throughout the forecast period.
  • By distribution channel, the offline segment held the largest share of the market in 2023.
  • By distribution channel, the offline segment is observed to expand at the fastest rate during the forecast period.

Antidepressant Drugs Market Size 2024 To 2033

Report Summary

The global antidepressant drugs market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the antidepressant drugs market across the globe.

A comprehensive estimate on the antidepressant drugs market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of antidepressant drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3698

Antidepressant Drugs Market Scope

Report CoverageDetails
Global Market Size in 2023USD 18.5 Billion
Global Market Size by 2033USD 25.22 Billion
U.S. Market Size in 2023USD 6.02 Billion
U.S. Market Size by 2033USD 8.37 Billion
Base Year2023
Forecast Period2024 to 2033
Segments CoveredBy Product, By Depressive Disorder, and By Distribution Channel
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized antidepressant drugs market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Aspiration Tubing Market Size to Rise USD 11.46 Bn By 2033

Market Players

The report includes the profiles of key antidepressant drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Recent Developments

  • In August 2023, The U.S. Food and Drug Administration (FDA) has approved ZURZUVAE 50 mg for individuals with postpartum depression (PPD), according to a statement from Biogen Inc. and Sage Therapeutics, Inc. For women with PPD, ZURZUVAE is the first and sole oral, once-daily, 14-day medication that can significantly reduce depression symptoms.

Antidepressant Drugs Market Companies

  • GlaxoSmithKline PLC
  • Sanofi
  • AstraZeneca
  • Eli Lilly and Company
  • Pfizer Inc

Segments Covered in the Report

By Product

  • Selective Serotonin Reuptake Inhibitors
  • Serotonin Norepinephrine Reuptake Inhibitors
  • Tricyclic Antidepressant
  • Monoamine Oxidase Inhibitor
  • Others

By Depressive Disorder

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others.

By Distribution Channel

  • Offline
  • Online

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antidepressant Drugs Market 

5.1. COVID-19 Landscape: Antidepressant Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antidepressant Drugs Market, By Product

8.1. Antidepressant Drugs Market Revenue and Volume, by Product, 2024-2033

8.1.1 Selective Serotonin Reuptake Inhibitors

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Serotonin Norepinephrine Reuptake Inhibitors

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Tricyclic Antidepressant

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Monoamine Oxidase Inhibitor

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Antidepressant Drugs Market, By Depressive Disorder

9.1. Antidepressant Drugs Market Revenue and Volume, by Depressive Disorder, 2024-2033

9.1.1. Major Depressive Disorder

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Obsessive-Compulsive Disorder

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Generalized Anxiety Disorder

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Panic Disorder

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Antidepressant Drugs Market, By Distribution Channel 

10.1. Antidepressant Drugs Market Revenue and Volume, by Distribution Channel, 2024-2033

10.1.1. Offline

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Online

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Antidepressant Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 12. Company Profiles

12.1. GlaxoSmithKline PLC

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Sanofi

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. AstraZeneca

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Eli Lilly and Company

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pfizer Inc

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com